On Tuesday, Black Diamond Therapeutics Inc (NASDAQ: BDTX) opened lower -12.28% from the last session, before settling in for the closing price of $1.67. Price fluctuations for BDTX have ranged from $1.20 to $7.66 over the past 52 weeks.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Company’s average yearly earnings per share was noted 56.48% at the time writing. With a float of $43.15 million, this company’s outstanding shares have now reached $56.64 million.
In an organization with 24 employees, it is important to assess its efficiency. In terms of profitability, gross margin is 0.0%, operating margin of 0.0%, and the pretax margin is 0.0%.
Black Diamond Therapeutics Inc (BDTX) Insider Updates
A key investor’s attitude towards the stock of the Biotechnology industry is another important factor to consider. The insider ownership of Black Diamond Therapeutics Inc is 23.86%, while institutional ownership is 64.72%. The most recent insider transaction that took place on Mar 19 ’25, was worth 11,997,749. In this transaction 10% Owner of this company sold 5,784,292 shares at a rate of $2.07, taking the stock ownership to the 2,733,547 shares. Before that another transaction happened on Aug 28 ’24, when Company’s 10% Owner sold 221,600 for $6.32, making the entire transaction worth $1,400,556. This insider now owns 3,726,341 shares in total.
Black Diamond Therapeutics Inc (BDTX) Performance Highlights and Predictions
According to the Wall Street analysts, stocks earnings will be around 56.48% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will plunge by -0.85% during the next five years compared to -5.22% drop over the previous five years of trading.
Black Diamond Therapeutics Inc (NASDAQ: BDTX) Trading Performance Indicators
Check out the current performance indicators for Black Diamond Therapeutics Inc (BDTX). In the past quarter, the stock posted a quick ratio of 4.92.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -1.27, a number that is poised to hit 0.20 in the next quarter and is forecasted to reach -0.97 in one year’s time.
Technical Analysis of Black Diamond Therapeutics Inc (BDTX)
Let’s dig in a bit further. During the last 5-days, its volume was 0.84 million. That was inferior than the volume of 2.69 million it reported in year-ago period. As of the previous 9 days, the stock’s Stochastic %D was 51.51%. Additionally, its Average True Range was 0.14.
During the past 100 days, Black Diamond Therapeutics Inc’s (BDTX) raw stochastic average was set at 16.67%, which indicates a significant decrease from 33.33% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 79.54% in the past 14 days, which was lower than the 80.47% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $1.6452, while its 200-day Moving Average is $3.1391. However, in the short run, Black Diamond Therapeutics Inc’s stock first resistance to watch stands at $1.5933. Second resistance stands at $1.7167. The third major resistance level sits at $1.7833. If the price goes on to break the first support level at $1.4033, it is likely to go to the next support level at $1.3367. Assuming the price breaks the second support level, the third support level stands at $1.2133.
Black Diamond Therapeutics Inc (NASDAQ: BDTX) Key Stats
There are currently 56,677K shares outstanding in the company with a market cap of 83.03 million. Presently, the company’s annual sales total 0 K according to its annual income of -69,680 K. Last quarter, the company’s sales amounted to 0 K and its income totaled -15,990 K.
